VRTX Q4 2021 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.1B+27.3% YoY

Gross Profit

$1.8B88.1% margin

Operating Income

$878M42.3% margin

Net Income

$770M37.2% margin

EPS (Diluted)

$3.00

QoQ Revenue Growth

+4.5%

Cash Flow

Operating Cash Flow

$995M

Free Cash Flow

$933M

Stock-Based Comp.

$119M

Balance Sheet

Total Assets

$13.4B

Total Liabilities

$3.3B

Stockholders' Equity

$10.1B

Cash & Equivalents

$6.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.1B	$1.6B	+27.3%
Gross Profit	$1.8B	$1.4B	+28.1%
Operating Income	$878M	$746M	+17.7%
Net Income	$770M	$604M	+27.5%

Revenue Segments

TRIKAFTA/KAFTRIO

$1.7B82%

KALYDECO

$152M7%

ORKAMBI

$147M7%

SYMDEKO/SYMKEVI

$80M4%

Geographic Segments

UNITED STATES

$1.4B67%

Europe

$590M28%

Other, Non U.S.

$88M4%